WINT - Windtree Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
4.0000
0.0000 (0.00%)
At close: 1:34PM EST
Stock chart is not supported by your current browser
Previous Close4.0000
Open2.6800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.0000 - 4.0000
52 Week Range2.0400 - 5.3500
Volume24
Avg. Volume873
Market Cap128.756M
Beta (3Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-1.6730
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.30
  • Windtree Therapeutics Provides Business Update
    PR Newswire

    Windtree Therapeutics Provides Business Update

    WARRINGTON, Pa., Oct. 25, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today provided updates on its lead development programs and business operations. "During the third quarter, we made substantive progress in two of our lead development programs – istaroxime for acute heart failure (AHF) and early cardiogenic shock, and AEROSURF® for respiratory distress syndrome (RDS) in premature infants.

  • GlobeNewswire

    Windtree Therapeutics to Present at the Fall Investor Summit

    WARRINGTON, Pa., Sept. 10, 2019 -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and.

  • Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant
    PR Newswire

    Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant

    WARRINGTON, Pa., Sept. 6, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the full publication of previously described results of a lung deposition study conducted in non-human primates (NHPs) that demonstrated the Company's proprietary aerosol delivery system (ADS) is capable of delivering aerosolized lucinactant (the Company's lyophilized KL4 surfactant) throughout all regions of the lung. The study was performed in collaboration with Lovelace Biomedical and is published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. The study consisted of a series of experiments in NHPs designed to assess the distribution and deposition of aerosolized lucinactant in the lung when administered using the ADS. The Company has developed the ADS as part of its AEROSURF® (lucinactant for inhalation) development program.

  • PR Newswire

    Windtree Therapeutics Reports Second Quarter 2019 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa. , Aug. 14, 2019 /PRNewswire/ --   Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device ...

  • PR Newswire

    Windtree Announces FDA Fast Track Designation for Istaroxime

    WARRINGTON, Pa., Aug. 13, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for istaroxime for the treatment of acute heart failure.

  • Windtree Therapeutics to Host Research & Development Day in New York City on June 25
    PR Newswire

    Windtree Therapeutics to Host Research & Development Day in New York City on June 25

    WARRINGTON, Pa., June 19, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced today that it will host a research and development (R&D) day in New York City on Tuesday, June 25 from 8:00 am – 9:30 am EDT. The R&D Day will feature presentations of Windtree's two lead therapeutic areas of acute heart failure and respiratory distress syndrome in premature infants delivered by key thought leaders in these respective fields.  Marco Metra, MD, from the University and Civil Hospitals of Brescia, Italy, will discuss the current treatment landscape and unmet medical need in treating patients with heart failure, and Fernando Moya, MD, from the Coastal Children's Services and New Hanover Regional Medical Center, will discuss the unmet medical need in treating premature infants with respiratory distress syndrome.

  • Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology
    PR Newswire

    Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology

    WARRINGTON, Pa. and PRINCETON, N.J., June 4, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, and Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, today jointly announced positive results of the feasibility study using Windtree's proprietary Aerosol Delivery System (ADS) aerosolization technology to deliver Eleison's inhaled lipid cisplatin (ILC).

  • Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress
    PR Newswire

    Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress

    WARRINGTON, Pa., May 30, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the presentation of new safety and efficacy data from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at a late-breaker session of the European Society of Cardiology (ESC) 2019 Heart Failure Congress. The study achieved its primary endpoint by demonstrating a significant improvement (p

  • Windtree Therapeutics Reports First Quarter 2019 Financial Results and Provides Key Business Updates
    PR Newswire

    Windtree Therapeutics Reports First Quarter 2019 Financial Results and Provides Key Business Updates

    - Operational Integration of CVie Therapeutics Completed, and Advancement of Lead Programs Istaroxime and AEROSURF® Remains on Track - WARRINGTON, Pa. , May 20, 2019 /PRNewswire/ -- Windtree Therapeutics, ...

  • New Phase 2b Analysis Suggests AEROSURF® may Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS
    PR Newswire

    New Phase 2b Analysis Suggests AEROSURF® may Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS

    WARRINGTON, Pa., May 9, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT) today announced the results of a new post-hoc analysis of previously released phase 2 data that suggests AEROSURF® may reduce the overall incidence and severity of bronchopulmonary dysplasia (BPD) in premature infants with respiratory distress syndrome (RDS), regardless of whether or not the infant was ultimately intubated.

  • Windtree Therapeutics Appoints Daniel Geffken to Board of Directors
    PR Newswire

    Windtree Therapeutics Appoints Daniel Geffken to Board of Directors

    WARRINGTON, Pa., April 30, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biopharmaceutical and medical device company focused on developing novel therapies to address significant unmet needs in important acute care markets, today announced it has appointed Daniel Geffken to the Company's Board of Directors, effective April 24, 2019. "As we continue to support Windtree in the delivery of near-term and sustainable growth, it is with great pleasure that we welcome Daniel to our Board," said James Huang, Windtree's Chairman of the Board.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Windtree Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Jan. 2, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • PR Newswire

    Windtree Therapeutics to Hold Investor Call Thursday, January 3, 2019 at 8:00 a.m. EST

    Previously Announced Call to Discuss Merger with CVie Therapeutics, $39 Million Private Placement, New Products Overview and Plans for 2019 WARRINGTON, Pa. , Jan. 2, 2019 /PRNewswire/ -- Windtree Therapeutics, ...

  • PR Newswire

    Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases

    WARRINGTON, Pa. and TAIPEI, Taiwan, Dec. 21, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and CVie Investments Limited (CVie), together with its wholly-owned subsidiary, CVie Therapeutics Limited, a privately-held company focused on developing drugs to treat cardiovascular diseases, today announced the closing of a definitive agreement for the merger of a Windtree Therapeutics subsidiary and CVie in an all-stock transaction. The combined company, which will retain the name Windtree Therapeutics, will be a fully-integrated and diversified acute care company with four mid-to-late clinical stage product assets and multiple preclinical assets and programs.

  • New Data from the AEROSURF® Phase 2b Clinical Program shows AEROSURF® Appears to Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS
    PR Newswire

    New Data from the AEROSURF® Phase 2b Clinical Program shows AEROSURF® Appears to Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS

    Windtree Presents Data in Premature Infants 26 to 32 Weeks Gestational Age at the 2018 Hot Topics in Neonatology Annual Meeting WARRINGTON, Pa. , Dec. 10, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. ...